According to Destatis, the official German statistics agency, Germany's GDP grew just 0.4% in 2013. This is the lowest growth rate since the 5.1% drop registered in 2009, during the global financial crisis. The German government also finished the year with a 0.1% deficit, versus a 0.1% surplus in 2012. So, although it remains stable, the country might start to revert trends and fall into recession. Given the circumstances, let's see how some German ADRs are performing.
Still unaffected
First, Fresenius Medical Care (NYSE: FMS ) is the No. 1 global provider of dialysis equipment. It enjoys leading market share of almost 33% in its home country.
Fresenius continues to report good results despite the performance of the German economy. The first three quarters of 2013 showed a 9% growth in sales and a 12% increase in net income.
The combination of an aging global population and Fresenius' vertically integrated equipment division makes the company a competitive player in the health services industry. In fact, rising rates of obesity and diabetes can only raise demand for dialysis services going forward. So fundamentals are on the company's side.
5 Best Media Stocks To Own Right Now: Sequenom Inc.(SQNM)
Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock research. The company operates in two segments, Molecular Diagnostics and Genetic Analysis. The Molecular Diagnostics segment researches, develops, and commercializes noninvasive molecular diagnostic tests for prenatal genetic disorders and diseases, women?s health related disorders and diseases, ophthalmology, oncology, infectious diseases, and autoimmunity. This segment markets diagnostic technology for prenatal diagnostics under the trademark SEQureDx. The Genetic Analysis segment designs and markets MassARRAY system, a nucleic acid analysis platform that comprises hardware, software applications, consumable chips, and reagents to measure genetic target material and variations. This segment o ffers its MassARRAY system for various DNA/RNA analysis applications, including single nucleotide polymorphism (SNP), genotyping, detection of mutations, analysis of copy number variants, and other structural genome variations, as well as quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. It also provides iPLEX multiplexing assay, which permits multiplexed SNP analysis and somatic mutation analysis. The company offers its products through direct sales, and sales and distribution partners to clinical research laboratories, bio-agriculture, bio-technology and pharmaceutical companies, academic institutions, and various government agencies worldwide. Sequenom, Inc. was founded in 1994 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Selena Maranjian]
Finally, GMT Capital's biggest closed positions included Harris�and NII Holdings. Other closed positions of interest include Sequenom (NASDAQ: SQNM ) and QuestCor Pharmaceuticals (NASDAQ: QCOR ) . Sequenom, which makes molecular and genetic diagnostic tests, is a relatively small concern, with a market cap near $500 million. One of the company's tests checks for Down syndrome in a non-invasive manner, which should be of interest to many older women.�Future tests�might address conditions such as macular degeneration. Meanwhile, the company is expanding its reach abroad, but it's still posting widening losses along with strong revenue growth.
- [By Keith Speights]
2. Sequenom (NASDAQ: SQNM )
Sequenom and Lexicon have similar stories in one respect. Sequenom also started off roaring in 2000 only to fizzle out in subsequent years. Over the last decade, the genetic analysis company has seen shares decline by 54%.
Top 5 Performing Companies To Invest In Right Now: Ausdrill Ltd (ASL)
Ausdrill Limited is a mining and energy services company providing exploration, mine development, surfacing and underground mining, manufacturing, energy and infrastructure services globally. The Company operates in five segments: Mining Services Australia, which includes the provision of mining services, including drilling and blasting, in-pit grade control, exploration drilling, earthmoving, waterwell drilling, energy drilling, equipment hire, equipment parts and sales and mineral analysis in Australia; Contract Mining Services Africa, which includes the provision of mining services, including drilling and blasting, in pit grade control, exploration drilling and earthmoving in Africa; Manufacturing, which includes manufacture of drilling rods and consumables, drill rigs and dump truck tray bodies; Supply and Logistics, which includes the provision of mining supplies and logistics services and Other, which includes its central functions like treasury, financing and administration. Advisors' Opinion:- [By Adam Haigh]
Toyota Motor Corp. (7203), the world�� biggest carmaker, lost 1.3 percent in Tokyo after its net-income forecast fell short of analyst estimates. Ausdrill Ltd. (ASL) slumped 29 percent in Sydney after the drilling contractor said its expects a lower profit. GungHo Online Entertainment Inc. gained 2.5 percent as Japan Exchange Group Inc. and Nikkei Inc. said the Internet-game maker will be included in their new index.
Top 5 Performing Companies To Invest In Right Now: Flexpoint Sensor Systems Inc (FLXT)
Flexpoint Sensor Systems, Inc.(Flexpoint), incorporated on June 11, 1992, is a development stage company. The Company is principally engaged in designing, engineering and manufacturing bend sensor technology and products using its patented Bend Sensor technology. Flexpoint manufactures, and has jointly developed, six products that are being sold and supplied to customers. Flexpoint owns nine patents, including patents on specific devices that use the Bend Sensor. The Company works with various Tier 1 (major) automotive suppliers on a variety of products that are in various stages of development and implementation.
Bend Sensor Technology
Flexpoint owns the patent rights to the Company's Bend Sensor technology through Sensitron, Inc. (Sensitron), a wholly owned subsidiary of the Company. The Bend Sensor is a potentiometer bend sensor product consisting of a coated substrate, such as plastic, that changes electrical conductivity as it is bent in a consistent manner. Electronic systems can connect to this sensor and measure in detail the amount of bending or movement that occurs in a predictable manner. A potentiometer functions through the means of metal contacts swiping or rubbing across a resistive element. Flexpoin�� Bend Sensor potentiometer is a single layer with no mechanical assembly that makes it more reliable and smaller, and lighter in weight.
Automotive Products
Flexpoint has developed comfort seat for automobiles utilizing its patented Bend Sensortechnology and is working with Tier 1 suppliers on development of the seat and various seat related controls. Through a joint development arrangement with a Tier1supplier Flexpoint developed and delivered prototypes of the seat. Automobile manufacture has partnered with a Tier 1 supplier and is in the final stages of evaluating Flexpoint�� patented horn switch to replace their existing technology. The automobile manufacturer is also evaluating the use of the Bend Sensor as a switch to open rear! doors of SUV's and as a seat belt reminder (SBR). While working with various Tier 1 automotive suppliers the Company has developed and tested a SBR sensor that alerts the occupant of an automobile to fasten his/her seatbelt.
Flexpoint is working with multiple manufacturers to replace existing devices in the marketplace with a system superior in performance. Four separate and independent automotive suppliers and OEMs tested the Bend Sensor device for use in pedestrian impact detection device. The tests proved that the Bend Sensor device was able to detect impact with a human leg and in the event of an accident and trigger the desired safety response. Flexpoint has also developed a crash sensor, which is a series of sensors mounted in strategic places on the side and door panels of an automobile to detect an impact, as well as the speed, direction and force of the impact. This allows an onboard computer to deploy side air bags where needed. Using the same concept as the Company's automotive seat belt reminder (SBR), this device monitors cinema theater's paying customers and identifies available seats. Flexpoint has supplied a theater management firm with several prototype sensors, which have undergone extensive testing for this application.
As of December 31, 2012, Flexpoint developed and produced 20 prototype medical beds that assist in the management of bed sores. Using the Bend Sensor technology and accompanying electronics the bed is able to determine the position of the person in the bed and how they are moved. The Company has developed a vibration sensor, a rupture disc/bursting disc utilizing the Bend Sensor as the detection/alarm element of a rupture disc device, an infant bed cover using its patented sensors that is used to monitor infants in the prevention of sudden infant death syndrome (SIDS), toys and video gaming devices, and sports applications.
Advisors' Opinion:- [By CRWE]
Today, FLXT has shed (-6.25%) down -0.0060 at $.0900 with 19,500 shares in play thus far (ref. google finance Delayed: 11:10AM EDT September 25, 2013).
Flexpoint Sensor Systems, Inc. previously reported they expect to complete both Phase Two and Phase Three of development of the colonoscope application during the remainder of 2013. The company will receive milestone cash payments for each stage of the development process.
Top 5 Performing Companies To Invest In Right Now: Zalicus Inc.(ZLCS)
Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of drug candidates focusing on the treatment of pain and inflammation. The company?s clinical and preclinical product candidates for pain and inflammatory diseases include Synavive, a glucocorticoid product candidate, which is in Phase 2b clinical development for the treatment of rheumatoid arthritis; Z160, an N-type calcium channel blocker for chronic pain; Z944, a T-type calcium channel blocker to treat acute or chronic inflammatory pain; and N-type and T-type calcium and sodium channel blockers for the treatment of chronic pain. It has a research collaboration and license agreement with the Novartis Institutes of Biomedical Research; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and Amgen Inc; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases. The company was formerly known as C ombinatoRx, Incorporated and changed its name to Zalicus Inc. in September 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.
Advisors' Opinion:- [By Bryan Murphy]
The hot and cold cycle for Zalicus Inc. (NASDAQ:ZLCS) continues to repeat itself. The fourth such turn of that wheel looks like it's getting ready to begin, and if this is one anything like the last three, ZLCS is due for a rally of anywhere between 25% to 50%. Traders who hop on that wave shouldn't tarry, however, because if the budding rally is anything like the last three, it's still only going to lead to a pullback about half the size of the gain. Still, a sizeable double-digit gain isn't bad for a few days' worth of work.
- [By Paul Ausick]
Stocks on the Move: ViroPharma Inc. (NASDAQ: VPHM) is up 25.4% at $49.38 on a $4.2 billion buyout offer from London-listed Shire. Zalicus Inc. (NASDAQ: ZLCS) is down 72.3% at $1.30 on a failed drug trial.
- [By John Udovich]
Yesterday, shares of small cap pain stock�Zalicus Inc (NASDAQ: ZLCS) caused�recent investors some extreme plain�when shares plunged 72.28% (but�are still up 100% since the start of the year) after drug candidate Z160 failed two mid-stage clinical trials���meaning�its probably time to take an objective look at what to do with this stock (as it intends to�focus on its pain treatment Z944) plus take a look at the performance of biotech industry benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
No comments:
Post a Comment